Clinical Trial

Self- Sampling in Cervical Cancer Routine Screening

Study acronym: FALCON
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
SELF-SAMPLING IN CERVICAL CANCER ROUTINE SCREENING (FALCON) -Study implements a self-sampling option for the non-attendees of the national cervical cancer screening program in the Wellbeing Services County of Pirkanmaa. HPV primary testing is currently preferred method for cervical cancer screening. The HPV-DNA self-sampling has been shown to have screening performance equal to that of provider-obtained samples. In 2024, those turning 30, 35, 40, 45, 50, 55, 60, or 65 had the opportunity to participate in the FALCON study if they do not respond to the first invitation to cervical cancer screening. From March 2025 also women living in Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia can take part to the study. The main objective of the FALCON study is to increase the current coverage of the cervical cancer screening program in the Pirkanmaa, Kanta-Häme, Central Finland, Päijät-Häme, and Ostrobothnia region and assess how acceptable self-sampling is for women.
Trial Details
NCT Number NCT06931184
Lead Sponsor Tampere University Hospital
Conditions Cervical Cancer Screening
Enrollment 40,000 participants
Start Date 2024-06-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-17